Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan/HDS induction followed by trifluridine–tipiracil + bevacizumab vs trifluridine–tipiracil + bevacizumab alone in refractory metastatic colorectal cancer
2024-520356-24-00Phase 2Authorised
- Sponsor
- Delcath Systems
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of melphalan in colorectal cancer (CRC) (2 arms), sponsored by Delcath Systems. Primary endpoint: Hepatic progression-free survival (hPFS). Planned start Jul 2025; status: authorised.
02
Drugs
melphalan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-520356-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520356-24-00.